Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Divestiture, Clinical Study Updates, New Drug Application, and Quarterly Report - Research Report on Geron, NPS, Portola,



   Divestiture, Clinical Study Updates, New Drug Application, and Quarterly
Report - Research Report on Geron, NPS, Portola, MannKind, and Exact Sciences

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, October 21, 2013

NEW YORK, October 21, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Geron
Corporation (NASDAQ: GERN), NPS Pharmaceuticals, Inc. (NASDAQ: NPSP), Portola
Pharmaceuticals, Inc. (NASDAQ: PTLA), MannKind Corp. (NASDAQ: MNKD), and Exact
Sciences Corporation (NASDAQ: EXAS). Today's readers may access these reports
free of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Geron Corporation Research Report

On October 1, 2013, Geron Corporation (Geron) reported the completion of the
transaction for the divestiture of its stem cell assets, following an Asset
Contribution Agreement it had entered with BioTime, Inc. (BioTime) and
Asterias Biotherapeutics, Inc. (Asterias). Geron informed that it received
approximately 6.5 million shares of Asterias Series A common stock, and it
will receive royalties from Asterias for the sale of products that are
commercialized, if any, in reliance upon Geron patents acquired by Asterias.
The Company stated that it will distribute the Asterias Series A common stock
received from Asterias to Geron's stockholders on a pro rata basis ("Series A
Distribution"), other than with respect to fractional shares and stockholders
in certain to-be-determined excluded jurisdictions, who will instead receive
cash on a pro rata basis. According to Geron, it will set a record date,
following notice from BioTime and Asterias that certain securities
registration or qualification requirements have been met. Only Geron
stockholders as of that record date will be eligible to participate in the
Series A Distribution. The Full Research Report on Geron Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/1ca9_GERN]

--

NPS Pharmaceuticals, Inc. Research Report

On October 14, 2013, NPS Pharmaceuticals, Inc. (NPS) announced new findings
from its STEPS 2 study supporting the long-term use of Gattex (teduglutide
[rDNA origin]) for injection in adult patients with Short Bowel Syndrome
(SBS). NPS further reported that Gattex is indicated for the treatment of
adult patients with Short Bowel Syndrome who are dependent on parenteral
support in the US. Lauren Schwartz, MD, Assistant Professor of Medicine, Mount
Sinai School of Medicine, and Study Investigator, commented, "We are pleased
to see that long-term treatment with Gattex resulted in clinically meaningful
reductions in parenteral support as seen in the previous STEPS study."
Schwartz added, "Further, it is particularly encouraging that 13 patients
achieved complete independence from parenteral support with long-term Gattex
therapy. The ability to reduce or even completely eliminate the need for
parenteral support could meaningfully impact the lives of patients with this
rare and debilitating condition." The Full Research Report on NPS
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/441a_NPSP]

--

Portola Pharmaceuticals, Inc. Research Report

On October 9, 2013, Portola Pharmaceuticals, Inc. (Portola) announced that it
has initiated a Phase 1/2 clinical study of PRT2070, a novel, oral, dual
spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor. According to
Portola, the compound is being developed for patients with genetically-defined
hematologic cancers, as well as for patients who have failed therapy due to
relapse or acquired mutations. John T. Curnutte, M.D., Ph.D., Executive Vice
President of Research and Development for Portola, stated, "We are pleased to
advance our third wholly-owned program focused on addressing an unmet medical
need into the clinic. Our goal with PRT2070 is to develop an effective and
well- tolerated oral drug for the thousands of lymphoma and leukemia patients
who are impacted by difficult- to-treat genetic subtypes or who become
unresponsive to available therapies." Curnutte continued, "With PRT2070, we
have seen promising in vitro activity in cell lines with specific mutations
and in tumor cells that have lost sensitivity to other compounds due to
acquired mutations. We look forward to seeing initial clinical data for this
agent in 2014." The Full Research Report on Portola Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/102f_PTLA]

--

MannKind Corp. Research Report

On October 14, 2013, MannKind Corp. (MannKind) announced that it has
resubmitted a new drug application (NDA) to the US Food and Drug
Administration (FDA) on October 13, 2013, seeking approval for the marketing
and sale of AFREZZA (insulin human [rDNA origin]) Inhalation Powder with an
indication to improve glycemic control in adults with type 1 or type 2
diabetes. MannKind reported that the resubmission is based on the entire data
set from the extensive AFREZZA clinical development program and particularly
the positive results from two recent Phase 3 trials, one in patients with type
1 diabetes (study 171) and one in patients with type 2 diabetes (study 175).
Alfred Mann, Chairman and CEO of MannKind stated, "We designed the recent
studies with input and guidance from the FDA, and both achieved their primary
efficacy endpoints and safety objectives." The Full Research Report on
MannKind Corp. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.AnalystsCorner.com/r/full_research_report/044e_MNKD]

--

Exact Sciences Corporation Research Report

On October 16, 2013, Exact Sciences Corporation (Exact Sciences) announced
that it will host its Q3 2013 conference call on October 29, 2013 at 10:00
a.m. ET / 9:00 a.m. CT. The Company reported that the live and archived
version of the webcast is accessible through its website. The Full Research
Report on Exact Sciences Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.AnalystsCorner.com/r/full_research_report/9c49_EXAS]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement